CEFUROXIME SODIUM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cefuroxime Sodium, and what generic alternatives are available?
Cefuroxime Sodium is a drug marketed by Acs Dobfar Spa, Fresenius Kabi Usa, Hikma, Hospira Inc, Teva Pharms, Watson Labs Inc, and Samson Medcl. and is included in fourteen NDAs.
The generic ingredient in CEFUROXIME SODIUM is cefuroxime sodium. There are sixty-two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the cefuroxime sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cefuroxime Sodium
A generic version of CEFUROXIME SODIUM was approved as cefuroxime sodium by ACS DOBFAR SPA on May 30th, 1997.
Summary for CEFUROXIME SODIUM
US Patents: | 0 |
Applicants: | 7 |
NDAs: | 14 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 104 |
Clinical Trials: | 3 |
Patent Applications: | 919 |
Formulation / Manufacturing: | see details |
DailyMed Link: | CEFUROXIME SODIUM at DailyMed |
Recent Clinical Trials for CEFUROXIME SODIUM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Hospital Universitari Vall d'Hebron Research Institute | Phase 4 |
University Hospital, Basel, Switzerland | Phase 4 |
PriCara, Unit of Ortho-McNeil, Inc. | Phase 2/Phase 3 |
Pharmacology for CEFUROXIME SODIUM
Drug Class | Cephalosporin Antibacterial |